Company Overview
Solid Biosciences Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops specialized therapies designed to address neuromuscular and cardiac diseases in the United States market. The company's primary operational focus centers on its lead product candidate, SGT-003, which is currently advancing through phase 1/2 clinical trials for the treatment of Duchenne muscular dystrophy, alongside the development of SGT-212 for Friedreich's ataxia. This biotechnology entity employs a workforce of 121 individuals and maintains a total market capitalization of $565.24M, reflecting its position as a mid-sized entity within the specialized therapeutic development landscape. The absence of reported annual revenue figures in the available data suggests that the company is in a pre-revenue or early-stage revenue generation phase, which is typical for biotechnology firms heavily invested in research and development before commercializing their pipeline assets.
Financial Health
The company reports a net income of $-174,324,992 over the trailing twelve months, while its EBITDA stands at $-177,570,000, indicating a significant cash burn rate that consumes the entirety of its generated revenue stream. With revenue growth data listed as N/A and gross margin, operating margin, and profit margin all recorded at 0.0%, the financial structure reveals that the company has not yet achieved commercial profitability, a common characteristic for firms in the early clinical stages where R&D expenses vastly outpace sales. The free cash flow is reported at $-99,700,752, signaling that the company is currently utilizing its cash reserves to fund operations and development rather than generating surplus liquidity from core business activities. Despite the negative earnings, the balance sheet retains $187.85M in cash against $21.16M in debt, resulting in a debt-to-equity ratio of 11.76, which highlights a highly leveraged capital structure relative to equity but maintains substantial cash buffers. The current ratio of 6.14 indicates a strong position in short-term liquidity management, as current assets significantly exceed current liabilities, providing ample coverage for immediate obligations. Furthermore, the return on equity is -109.9% and the return on assets is -53.2%, metrics that mathematically reflect the dilution of shareholder value and asset efficiency due to the substantial net loss incurred during this developmental period.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -4.13, a figure that inversely reflects the market's pricing of expected future losses rather than current profitability. The price-to-book ratio stands at 3.18, suggesting that the market values the company at more than three times its book value, which may imply confidence in the intrinsic value of the intellectual property and pipeline assets despite the lack of current earnings. Alternative valuation measures such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -2.96, further underscore that traditional multiple-based valuation models are not applicable in the conventional sense for a company with no sales and negative earnings power. The stock trades between a 52-week high of $8.72 and a 52-week low of $2.41, meaning the current market price sits at a specific point within this volatility range that investors must evaluate against the high-risk profile of the asset. The beta value of 2.76 indicates that the stock price is highly volatile and moves with significantly greater magnitude than the broader market, exposing investors to substantial price swings that are characteristic of small-cap biotechnology equities.
Growth & Income
The company exhibits N/A for both revenue growth and earnings growth year-over-year, as the lack of historical revenue data prevents the calculation of growth rates, implying that any future earnings trajectory will depend entirely on the successful commercialization of its clinical pipeline. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the entity retains all available capital to reinvest into research and development rather than distributing income to shareholders. This reinvestment strategy is necessitated by the 0.0% profit margin and the need to sustain cash burn to progress clinical trials, effectively precluding any near-term income generation for investors. Consequently, the overall growth and income profile is defined by high capital expenditure requirements and the potential for significant value creation only upon the successful approval and market entry of therapeutic candidates like SGT-003 and SGT-212.